Resources
5 Results (showing 1 - 5)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/2/2021 (updated 4/4/2024)
In light of the accelerating and rapidly evolving overdose crisis in the United States (US), new strategies are needed to address the epidemic and to efficiently engage and retain individuals in care for opioid use disorder (OUD). Moreover, there is an increasing need for novel approaches to using health data to identify gaps in the cascade of care for persons with OUD.
Posted 2/3/2021 (updated 4/4/2024)
The opioid epidemic is the result of a complex system of varied and interrelated factors. This webinar introduced a systems thinking approach and tools to address such complex public health challenges. The Georgia Health Policy Center’s Opioid Systems Map was presented as a case study for the creation and application of systems mapping in local communities. The webinar fostered a holistic view of the opioid epidemic and described opportunities to further develop systems thinking capacity for application to grantees’ local opioid response.
Posted 6/17/2021 (updated 4/2/2024)
Telemedicine is increasingly being used to treat patients with opioid use disorder (OUD). It has particular value in rural areas of the United States impacted by the opioid crisis as these areas have a shortage of trained addiction medicine providers. Patient satisfaction significantly impacts positive clinical outcomes in OUD treatment and thus is of great clinical interest.
Posted 2/29/2024 (updated 3/28/2024)
The 2024 RCORP-Behavioral Health Care Support Onboarding Packet includes resources, tools, and strategies to support grant-funded activities, along with information on accessing TA.
Posted 3/22/2022 (updated 3/27/2024)
The purpose of this document is to provide detailed guidelines of the Nurse Care Manager Model of Office Based Addiction Treatment program for management of substance use disorders, with particular emphasis on treatment of opioid use disorder with buprenorphine (alone and in combination with naloxone) and naltrexone (oral and extended-release injectable formulations).